Company, product, and industry FAQs

Clarrio.ai brings together a longitudinal health data platform, a patient and member app, and an intelligence layer. The Platform organizes records into professional views, cohorts and research outputs. The Patient App captures structured check-ins and connected-source observations. Intelligence supports questions and source-linked summaries over the accessible record. A program can combine these workflows around its intended use; the exact scope is agreed for each deployment.

The site describes workflows for longevity and preventive-health clinics, pharma and biotech teams, CROs, and hospitals and health systems. Their questions differ: a clinic may need a member trajectory, a sponsor a defined cohort, and a research operations team a consistent follow-up record. Payer-facing evidence requirements and patient or member experience are considered separately rather than treating every stakeholder as the same user.

A wearable observation is one part of the record, not the whole program. Clarrio.ai's approach connects device observations with clinical information, labs and self-reported context over time. The useful question is not simply what changed, but when it changed, which source recorded it and what else was happening. A fuller record still requires quality checks and professional interpretation.

Clarrio.ai has a presence in Boston in the United States, France, Qatar and Tunisia. Global presence is distinct from where program data is hosted or processed. Hosting location, access arrangements and legal responsibilities need to be reviewed for each deployment; a location listing is not a data-residency commitment.

Bring your target population, care or research workflow, source systems and the questions your team needs to answer. Identify who collects information, who reviews it and who needs an output. A useful discussion also covers reporting burden, consent, integration dependencies and evaluation criteria. Do not send identifiable patient information through the public website. Use the contact page to send a written inquiry. To book a discussion directly, use the scheduling link, which opens Calendly in a new tab.

A clinic can design a record that places periodic assessments beside wearable observations and member check-ins. Program teams can review trajectories with the timing of visits, routines and reported context. Members can see personal trends in the app. This supports a more informed follow-up conversation; an association in the record should not be interpreted as proof that a particular action caused a change.

Start with the program's intended use rather than the largest possible data bundle. Consider clinical assessments, appropriate biomarkers, sleep or activity observations and member-reported experience, with a defined baseline and follow-up cadence. Check validity, units, device changes and reporting burden. A measure should have an explicit purpose and reviewer; collecting more signals does not automatically make the interpretation stronger.

A personal trajectory describes observations for an individual over time. Population evidence examines a defined group using explicit eligibility, measures and analysis methods. Neither automatically answers the other's question: a cohort average may conceal individual variation, while an individual's change cannot establish a general effect. Both require attention to missing observations, changing context and follow-up duration.

The Patient App offers structured check-ins, connected-source data and views of personal patterns. The aim is to bring the person's experience into the longitudinal record and make follow-up conversations more contextual. Program design must still consider accessibility, burden and understandable feedback. Health improvement, engagement or adherence should be evaluated in the specific program rather than promised from access to an app.

Relevant workflows include between-visit patient experience, patient services, long-term follow-up, rare-disease natural-history work and real-world evidence research. Platform views and exports can support a defined research question when the data and methods are fit for that use. A program should specify its population, variables, follow-up, review responsibilities and evidence limitations before deciding what to collect.

No. Real-world data consists of observations collected in care or everyday settings. Real-world evidence comes from analyzing suitable data to answer a specified question. An organized export is a starting point, not a conclusion. Relevance, reliability, bias, confounding and an appropriate analysis plan determine what can responsibly be inferred. Regulatory acceptance depends on the intended use and applicable requirements.

Clarrio.ai is positioned to work alongside sponsors and CROs, not to replace their operational responsibilities. Data schedules, instruments, participant communications and review procedures need study-specific approval. Any use within a study must align with the protocol and governance arrangements; a configurable workflow is not permission to alter endpoints or collect additional information without review.

Select an instrument for the intended concept, population and setting, then check its validation, licensing, language versions and administration requirements. Define the schedule and how missed responses will be handled. Short check-ins can add context but are not interchangeable with validated instruments. Completion rates describe participation; they do not by themselves establish a meaningful change in patient experience.

Continuity, source consistency and transparent limits are especially important when cohorts are small or follow-up is uneven. Teams should define measurement schedules, record source or instrument changes and distinguish non-response from an absence of symptoms. Natural-history observations can help describe trajectories, but comparability and selection effects require careful analysis before making broader inferences.

The Platform is described as an insight layer connecting clinical and between-visit information rather than a replacement for the EHR. A health system can explore longitudinal records and cohorts while retaining its existing clinical workflow. Source access, identity matching, terminology and the destination for each output must be agreed with the organization. A standards-based approach does not remove integration or governance work.

Payers need a clearly defined population, relevant outcomes, a credible comparator where appropriate and enough follow-up to interpret results. They also need to understand selection effects, missingness, uncertainty and applicability to their population. Clarrio.ai can support the organization of longitudinal data for evidence work, but a dashboard alone does not establish value, coverage eligibility or a reimbursement decision.

Teams may value source-linked context, consistent cohort definitions and clearer review handoffs. Patients or members may value a manageable reporting experience and a record that includes their perspective. These are different outcomes and should be evaluated separately. Efficient review is not proof of better health, and higher reporting activity is not proof of a useful patient experience.

No outcome or savings guarantee is presented here. Evaluation should distinguish operational measures, data quality, patient experience and health outcomes, using methods appropriate to each. Synthetic demonstrations and illustrative scenarios explain workflows; they are not customer results or benchmarks. Program-specific evidence needs review before it supports a broader claim.

The site describes clinical records, lab and biomarker data, wearable and device observations, and structured self-reports. Platform integration descriptions include FHIR and HL7 exchange and terminology such as LOINC and SNOMED CT. The available sources and mapping requirements depend on each implementation. Device coverage or a named EHR reference should not be taken as universal, immediately available connectivity.

Intelligence supports questions, trajectory summaries and trend exploration over the accessible harmonized record, with source-linked context for review. An answer is constrained by data coverage, quality and access. Missing observations should remain visible; generated text is not a substitute for a qualified professional's judgment. Task-specific evaluation and human review remain necessary for the intended use.

Clarrio.ai is presented as a research-oriented health data, interoperability and analytics platform. It is not presented as an autonomous clinical decision-maker. Qualified professionals retain responsibility for clinical decisions, and a source-linked trend or summary is not in itself a clinical conclusion. The intended use and appropriate review boundaries should be established before deployment.

Review the purpose of processing, consent or other applicable legal basis, authorized roles, retention, hosting location and agreements for the specific program. Corporate presence does not determine data residency. Detailed controls should be confirmed through due diligence.

Timing depends on source access, mappings, program configuration, governance review and validation. Begin with a bounded workflow and agreed acceptance criteria, then check that data reaches the right view with its source context intact. No universal implementation deadline is promised here. A deployment plan should identify dependencies, reviewers and what must be demonstrated before wider use.

Yes. "Beyond the clinical trial: longitudinal real-world evidence across the drug lifecycle" is available as a free PDF. The other topics on the whitepaper page are proposed and will be added after review for authorship, citations, version and scientific interpretation.